Biogen Inc Stock Filter Stocks by Fundamentals
BIIB Stock | USD 216.34 4.32 2.04% |
Biogen Inc fundamentals help investors to digest information that contributes to Biogen's financial success or failures. It also enables traders to predict the movement of Biogen Stock. The fundamental analysis module provides a way to measure Biogen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biogen stock.
As of March 29, 2024, Cash Per Share is expected to decline to 5.26. Biogen | Cash per Share |
Biogen Cash per Share Analysis
Current Biogen Cash per Share | 5.26 |
Most of Biogen's fundamental indicators, such as Cash per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biogen Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Biogen Cash per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Biogen is extremely important. It helps to project a fair market value of Biogen Stock properly, considering its historical fundamentals such as Cash per Share. Since Biogen's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Biogen's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Biogen's interrelated accounts and indicators.
Click cells to compare fundamentals
Biogen Cash per Share Historical Pattern
Today, most investors in Biogen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biogen's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Biogen cash per share as a starting point in their analysis.
Biogen Cash per Share |
Timeline |
Competition |
Biogen Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Did you try this?
Run Pair Correlation Now
Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments |
All Next | Launch Module |
Biogen ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Biogen's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Biogen's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Biogen Fundamentals
Return On Equity | 0.0824 | ||||
Return On Asset | 0.0458 | ||||
Profit Margin | 0.12 % | ||||
Operating Margin | 0.19 % | ||||
Current Valuation | 37.73 B | ||||
Shares Outstanding | 145.36 M | ||||
Shares Owned By Insiders | 0.68 % | ||||
Shares Owned By Institutions | 93.03 % | ||||
Number Of Shares Shorted | 2.66 M | ||||
Price To Earning | 14.83 X | ||||
Price To Book | 2.12 X | ||||
Price To Sales | 3.20 X | ||||
Revenue | 9.84 B | ||||
Gross Profit | 7.9 B | ||||
EBITDA | 2.6 B | ||||
Net Income | 1.16 B | ||||
Cash And Equivalents | 4.91 B | ||||
Cash Per Share | 34.10 X | ||||
Total Debt | 7.34 B | ||||
Debt To Equity | 0.52 % | ||||
Current Ratio | 2.49 X | ||||
Book Value Per Share | 102.14 X | ||||
Cash Flow From Operations | 1.55 B | ||||
Short Ratio | 2.30 X | ||||
Earnings Per Share | 7.96 X | ||||
Price To Earnings To Growth | 6.24 X | ||||
Target Price | 304.23 | ||||
Number Of Employees | 7.57 K | ||||
Beta | -0.024 | ||||
Market Capitalization | 31.45 B | ||||
Total Asset | 26.84 B | ||||
Retained Earnings | 17.63 B | ||||
Working Capital | 3.42 B | ||||
Current Asset | 8.73 B | ||||
Current Liabilities | 3.42 B | ||||
Z Score | 4.33 | ||||
Net Asset | 26.84 B |
About Biogen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biogen Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biogen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biogen Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported | Projected for 2024 | ||
Cash Per Share | 7.26 | 5.26 |
Pair Trading with Biogen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biogen will appreciate offsetting losses from the drop in the long position's value.Moving together with Biogen Stock
0.79 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
Moving against Biogen Stock
0.92 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
0.81 | MDWD | Mediwound Downward Rally | PairCorr |
0.78 | MGNX | MacroGenics Financial Report 14th of May 2024 | PairCorr |
0.56 | CLVRW | Clever Leaves Holdings | PairCorr |
0.54 | MDGL | Madrigal Pharmaceuticals Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Biogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biogen Inc to buy it.
The correlation of Biogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biogen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Biogen Piotroski F Score and Biogen Altman Z Score analysis. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Biogen Stock analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Biogen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.55) | Earnings Share 7.96 | Revenue Per Share 67.972 | Quarterly Revenue Growth (0.06) | Return On Assets 0.0458 |
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.